Eledon Pharmaceuticals (NASDAQ:ELDN) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Paul Little - Chief Financial Officer David-Alexandre Gros - Chief Executive Officer Steven Perrin - President & Chief Scientific Officer Jeff Bornstein - Chief Medical Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann Thomas Smith - SVB Leerink Rami Katkhuda - LifeSci Capital Vernon Bernardino - H.C. Wainwright Operator Greetings. Welcome to the Eledon Pharmaceuticals Re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36620 ELEDON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1000967 (State or other juri ...

Eledon Pharmaceuticals (NASDAQ:ELDN) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Jon Kuwahara - Senior Vice President of Finance David-Alexandre Gros - Chief Executive Officer Steve Perrin - President & Chief Scientific Officer Paul Little - Chief Financial Officer Conference Call Participants Li Watsek - Cantor Rami Katkhuda - LifeSci Capital Thomas Smith - SVB Leerink Matthew Kaplan - Ladenburg Thalmann Vernon Bernardino - H.C. Wainwright Operator Greetings, all, and welc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36620 ELEDON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1000967 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36620 ELEDON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1000967 (State or other jurisdi ...

Novus Therapeutics, Inc. (NVUS) Q3 2020 Earnings Conference Call November 16, 2020 4:30 PM ET Company Participants Jon Kuwahara - Senior Vice President of Finance David-Alexandre Gros - Chief Executive Officer Steve Perrin - President & Chief Scientific Officer Conference Call Participants Operator Good day and welcome to the Novus Therapeutics Third Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal pre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36620 NOVUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1000967 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36620 NOVUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1000967 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36620 NOVUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1000967 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36620 NOVUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1000967 (State or other jurisdictio ...